No registrations found.
ID
Source
Brief title
Health condition
Castration-resistant prostate cancer
Sponsors and support
Intervention
Outcome measures
Primary outcome
Diagnostic accuracy of 18F-FDHT PET/CT as a predictor of treatment response
Secondary outcome
Comparison of 'treatment response and clinical survival endpoints' versus 'no treatment response and clinical survival endpoints'
Background summary
Worldwide prostate cancer is the second most frequently diagnosed cancer in men. While localized prostate cancer can be treated with curative intent, metastasized prostate cancer has palliative treatment options only. Endocrine deprivation therapy is the mainstay of treatment for patients with metastasized prostate cancer. In the end, prostate cancer progresses in the majority of patients because of progressive tumor growth despite endocrine deprivation therapy: castration-resistant prostate cancer (CRPC). As CRPC progresses, approximately 90% of patients will develop bone metastases, in contrast to lymph node metastases which develop in 20% to 25% of patients. The determination of response to treatment in patients with CRPC is predominantly plagued by the presence of non-measurable bone metastases. Positron Emission Tomography (PET) is emerging as a promising imaging modality to evaluate treatment options and therapeutic response timely, objectively and quantitatively. 16β-[18F]-fluoro-5α-dihydrotestosterone (18F-FDHT) images the androgen receptor with high binding affinity and selectivity. It is expected that 18F-FDHTPET/CT can give an indication of success or failure early in the treatment course as part of clinical management or within the context of clinical trials. Timely response management may adjust the duration of individual treatment according to its success. This is where the FuTuRe trial comes in. The primary objective is to evaluate 18F-FDHT PET/CT as a predictor of response in patients with CRPC who are to be treated with enzalutamide.
Study objective
18F-FDHT PET/CT is expected to be a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide
Study design
Start 18F-FDHT PET/CT at baseline (prior to treatment), start enzalutamide at baseline, 18F-FDHT PET/CT after 4 weeks of treatment, follow-up visits on a monthly basis during the first year of the trial, afterwards once a quarter
Intervention
Enzalutamide
Hanzeplein 1
I.J. Jong, de
Groningen 9713 GZ
The Netherlands
0031503612380
i.j.de.jong@umcg.nl
Hanzeplein 1
I.J. Jong, de
Groningen 9713 GZ
The Netherlands
0031503612380
i.j.de.jong@umcg.nl
Inclusion criteria
Main inclusion criteria:
1. Age 50 or older.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
3. Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone analogue or bilateral orchidectomy.
4. Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease.
5. Metastatic disease documented by bone lesions on bone scan or by measurable soft tissue disease by CT
6. No prior cytotoxic chemotherapy for prostate cancer.
7. Asymptomatic or mildly symptomatic from prostate cancer.
8. Written informed consent.
Exclusion criteria
Main exclusion criteria:
1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
2. Known or suspected brain metastasis or active leptomeningeal disease.
3. History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3919 |
| NTR-old | NTR4086 |
| Other | : FuTuRe |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |